Antiepileptic drug pharmacogenetics

Therapeutic Drug Monitoring

Volumn 22, Issue 1, 2000, Pages 127-130

  Patsalos, Philip N ^a,b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b EPILEPSY SOCIETY   (United Kingdom)

Author keywords

Antiepileptic drugs; Genetic polymorphism; Pharmacogenetics

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ARTICLE; DOSE RESPONSE; DRUG METABOLISM; EPILEPSY; GENE CONTROL; GENETIC POLYMORPHISM; HUMAN; HYPERSENSITIVITY REACTION; NEUROCHEMISTRY; PHARMACOGENETICS; PRIORITY JOURNAL; SEIZURE; TERATOGENICITY;

ANTICONVULSANTS; DRUG RESISTANCE; EPILEPSY; HUMANS; PHARMACOGENETICS; TRANSCRIPTION FACTORS;

EID: 0033950743     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200002000-00027     Document Type: Article

References (14)

1. Patsalos PN. New antiepileptic drugs. Ann Clin Biochem 1999;36: 10-19.
2. Tishler DM, Weingerg KI, Hinten DR, Barbara N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995;36:1-6.
3. Ebert U, Loscher W. Characterisation of phenytoin-resistant kindled rats, a new model of drug-resistant partial epilepsy: influence of genetic factors. Epilepsy Res 1999;33:217-226.
4. Kutt H, Wolk M, Scherman R, McDowell F. Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity. Neurology 1964;14:542-548.
5. Mamiya K, Ieri I, Shimamoto J, et al. The effect of genetic polymorphisms of CYP2C9 and CYP2CI9 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 1998; 39:1317-1323.
6. Kubow S, Wells PG. In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthetase, horse-radish peroxidase, and thyroid peroxidase. Mol Pharmacol 1989; 35:504-511.
7. Furst SM, Sukhai P, McClelland RA, et al. Covalent binding of carbamazepine oxidative metabolites to neutrophils. Drug Metab Disp 1995;23:590-594.
8. Gaedigk A, Spielberg SP, Grant DM. Characterisation of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 1994;4:142-153.
9. Nakane Y, Okuma T, Takahashi T, et al. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 1980;21: 663-680.
10. Lidhout D, Hoppener RJEA, Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia 1984;25:77-83.
11. Kerr BM, Rettie AE, Eddy AC, et al. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation, Clin Pharmacol Ther 1989;46:82-93.
12. Strickler SM, Dansky LV, Miller MA, et al., Genetic predisposition to phenytoin induced birth defects. Lancet 1985;2:746-749.
13. Morgan JI, Curren T. Stimulas-transcription coupling in the nervous system: involvement of the inducible proto-ongogenes fos and jun. Annu Rev Neurosci 1991;14:421-451.
14. Gass P, Herdegen T. Neuronal expression of AP-1 proteins in excitotoxic-neurodegenerative disorders and following nerve fibre lesions. Prog Neurobiol 1995;47:257-290.